肿瘤坏死因子α抑制剂诱导的银屑病研究进展  

umor necrosis factor-αinhibitor-induced psoriasis

作　　者：孙杰[1] 王睿[1] 李承新[1] Sun Jie;Wang Rui;Li Chengxin(Department of Dermatology,The First Medical Center of Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院第一医学中心皮肤科,北京100853

出　　处：《中华皮肤科杂志》2022年第9期821-824,共4页Chinese Journal of Dermatology

基　　金：国家自然科学基金(81972936);首都临床特色应用研究项目(Z181100001718038);解放军总医院科技创新苗圃基金(18KMM10)。

摘　　要：近年来肿瘤坏死因子α(TNF-α)抑制剂用于治疗多种炎症性疾病取得显著疗效,但同时也出现了一种不容忽视的、矛盾的药物不良反应,即其可诱发部分患者出现银屑病样表现,称之为TNF-α抑制剂诱导的银屑病,病理表现可为银屑病样改变,也可为海绵状改变,发病机制可能与TNF-α和Ⅰ型干扰素之间平衡失调、白细胞介素23/Th17细胞轴参与、感染有关。本文对TNF-α抑制剂诱导的银屑病的流行病学、组织学特征及其可能的发病机制做一阐述,为识别和治疗TNF-α抑制剂诱导的银屑病提供依据。Tumor necrosis factor-α(TNF-α)inhibitors have been widely used and proven to be effective in the treatment of various inflammatory disorders in recent years,but there is a noteworthy and paradoxical adverse drug reaction that cannot be ignored,that is,TNF-α inhibitor-induced psoriasis.Its pathological manifestations could be psoriasiform or spongiotic changes,and its pathogenesis may be related to the imbalance between TNF-α and type Ⅰ interferon,the involvement of interleukin-23/T helper 17 axis,or infection.This review elaborates the epidemiological,histopathological features and possible pathogenesis of TNF-α inhibitor-induced psoriasis,and provides a basis for recognition and treatment of TNF-α inhibitor-induced psoriasis.

关 键 词：银屑病 肿瘤坏死因子Α 生物制剂 不良反应 肿瘤坏死因子α抑制剂诱导的银屑病 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]